Form 4: Cidara Therapeutics Director Acquires 16,000 Stock Options

A Cidara Therapeutics director, Carin Canale-Theakston, acquired 16,000 stock options on December 17, 2024.

Summary

• Carin Canale-Theakston, a director at Cidara Therapeutics, acquired 16,000 stock options on December 17, 2024.
• The options have an exercise price of $22.81.
• The options vest in 36 equal monthly installments starting from December 17, 2024.
• The options expire on December 16, 2034.

Sentiment

Score: 6

Explanation: The document is neutral, reporting a standard stock option grant to a director. It doesn't indicate any positive or negative sentiment about the company's performance.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a public company, often part of their compensation package.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 36 months is also a typical arrangement to incentivize long-term commitment.
• The exercise price is set at a level that is intended to align the director's interests with those of the shareholders.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, insider trading, Cidara Therapeutics, CDTX, equity